EU Bolsters COVID-19 Vaccine Supply with New Procurement Deal
The European Commission has signed a joint procurement contract with Spanish pharmaceutical company HIPRA for up to 4 million doses of its protein-based COVID-19 vaccine, Bimervax®, specifically adapted to the LP.8.1 variant. The agreement, signed at the request of 14 participating countries, aims to enhance EU preparedness and ensure citizens are protected against evolving COVID-19 threats ahead of the 2025-2026 winter season.
The contract, valid for up to two years, allows member states to order doses as needed, with no minimum purchase requirement. Vaccine delivery is scheduled to coincide with the upcoming vaccination season.
Commissioner for Equality, Preparedness and Crisis Management, hadja Lahbib, emphasized the importance of continued protection, particularly for vulnerable populations, given the emergence of new COVID-19 cases and variants. She highlighted the strategic benefits of the deal, stating, “This vaccine…strengthens our strategic autonomy and diversifies our portfolio of vaccines.”
The addition of Bimervax® expands the range of vaccine options available to EU citizens, offering a protein-based alternative to existing mRNA vaccines. HIPRAS vaccine has received Marketing Authorization from the European Commission following trials demonstrating immunity against the LP.8.1 variant, as well as cross-protection against other emerging sublineages including NB.1.8.1 and XFG.
Bimervax® is supplied in single-dose vials and benefits from convenient storage requirements (2°C to 8°C) and a 12-month shelf life. The vaccine works by introducing fragments of a viral protein to stimulate the body’s immune response.
A key advantage of this procurement is that HIPRA’s research and development,production,and fill-finish processes are all based within Europe,bolstering the EU’s supply chain resilience and reducing dependence on external sources for vaccine production.
This procurement is facilitated by the ‘Joint Procurement Agreement,’ a pre-existing EU mechanism established to collaboratively acquire medical countermeasures for public health emergencies. Currently, 38 countries have signed onto this agreement, demonstrating a unified approach to pandemic preparedness. Further facts is available on the European Commission’s health website.
